Adalimumab -: a new TNF-α antibody for treatment of inflammatory joint disease

被引：41

作者：

Machold, KP ^{[1
]}

Smolen, JS ^{[1
]}

机构：

[1] Univ Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2003年 / 3卷 / 02期

关键词：

adalimumab; D2E7; inflammation; monoclonal antibody; rheumatoid arthritis; rheumatology; TNF-alpha;

D O I：

10.1517/eobt.3.2.351.21148

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];

摘要：

Tumour necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine with various roles in inflammatory processes. Several TNF blockers are currently approved for use in rheumatoid arthritis (RA) as well as in other inflammatory arthropathies. The latest of these compounds is the human monoclonal antibody, adalimumab, which was obtained using phage display technology and successfully produced in a mammalian expression system. Clinical application of this compound led to significant improvement in patients suffering from RA, both as monotherapy and in combination with various disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX). Moreover, radiographic progression is significantly inhibited and quality of life improved. This article summarises the available information.

引用

页码：351 / 360

页数：10

共 92 条

[1]

The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses [J].

Aletaha, D ;

Smolen, JS .

RHEUMATOLOGY, 2002, 41 (12) :1367-1374

[2]

Aletaha D, 2002, J RHEUMATOL, V29, P1631

[3]

Alsalameh S, 1999, SCAND J IMMUNOL, V49, P278

[4]

CYTOKINES AND CYTOKINE INHIBITORS OR ANTAGONISTS IN RHEUMATOID-ARTHRITIS [J].

AREND, WP ;

DAYER, JM .

ARTHRITIS AND RHEUMATISM, 1990, 33 (03) :305-315

[5]

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis [J].

Barrera, P ;

van der Maas, A ;

van Ede, AE ;

Kiemeney, BALM ;

Laan, RFJM ;

van de Putte, LBA ;

van Riel, PLCM .

RHEUMATOLOGY, 2002, 41 (04) :430-439

[6]

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Genovese, MC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Finck, BK .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593

[7]

BOERS M, 1991, J RHEUMATOL, V18, P316

[8]

BRADLEY JR, 1995, AM J PATHOL, V146, P27

[9]

Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].

Braun, J ;

Brandt, J ;

Listing, J ;

Zink, A ;

Alten, R ;

Golder, W ;

Gromica-Ihle, E ;

Kellner, H ;

Krause, A ;

Schneider, M ;

Sörensen, H ;

Zeidler, H ;

Thriene, W ;

Sieper, J .

LANCET, 2002, 359 (9313) :1187-1193

[10]

BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293

← 1 2 3 4 5 6 7 8 9 10 →